148 related articles for article (PubMed ID: 16815442)
1. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
Slutzki M; Jaitin DA; Yehezkel TB; Schreiber G
J Mol Biol; 2006 Jul; 360(5):1019-30. PubMed ID: 16815442
[TBL] [Abstract][Full Text] [Related]
2. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
Piehler J; Schreiber G
J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
[TBL] [Abstract][Full Text] [Related]
3. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
Lamken P; Lata S; Gavutis M; Piehler J
J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
[TBL] [Abstract][Full Text] [Related]
4. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
[TBL] [Abstract][Full Text] [Related]
5. Shared receptor components but distinct complexes for alpha and beta interferons.
Lewerenz M; Mogensen KE; Uzé G
J Mol Biol; 1998 Sep; 282(3):585-99. PubMed ID: 9737924
[TBL] [Abstract][Full Text] [Related]
6. NMR backbone dynamics of the human type I interferon binding subunit, a representative cytokine receptor.
Chill JH; Quadt SR; Anglister J
Biochemistry; 2004 Aug; 43(31):10127-37. PubMed ID: 15287740
[TBL] [Abstract][Full Text] [Related]
7. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation.
Russell-Harde D; Wagner TC; Perez HD; Croze E
Biochem Biophys Res Commun; 1999 Feb; 255(2):539-44. PubMed ID: 10049744
[TBL] [Abstract][Full Text] [Related]
8. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.
Jaitin DA; Roisman LC; Jaks E; Gavutis M; Piehler J; Van der Heyden J; Uze G; Schreiber G
Mol Cell Biol; 2006 Mar; 26(5):1888-97. PubMed ID: 16479007
[TBL] [Abstract][Full Text] [Related]
9. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
[TBL] [Abstract][Full Text] [Related]
10. Differential receptor subunit affinities of type I interferons govern differential signal activation.
Jaks E; Gavutis M; Uzé G; Martal J; Piehler J
J Mol Biol; 2007 Feb; 366(2):525-39. PubMed ID: 17174979
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site.
Roisman LC; Jaitin DA; Baker DP; Schreiber G
J Mol Biol; 2005 Oct; 353(2):271-81. PubMed ID: 16171819
[TBL] [Abstract][Full Text] [Related]
12. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells.
Gazziola C; Cordani N; Carta S; De Lorenzo E; Colombatti A; Perris R
Int J Oncol; 2005 Jan; 26(1):129-40. PubMed ID: 15586233
[TBL] [Abstract][Full Text] [Related]
13. Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.
Piehler J; Schreiber G
J Mol Biol; 1999 May; 289(1):57-67. PubMed ID: 10339405
[TBL] [Abstract][Full Text] [Related]
14. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
15. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
Lamken P; Gavutis M; Peters I; Van der Heyden J; Uzé G; Piehler J
J Mol Biol; 2005 Jul; 350(3):476-88. PubMed ID: 15946680
[TBL] [Abstract][Full Text] [Related]
16. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.
Runkel L; deDios C; Karpusas M; Betzenhauser M; Muldowney C; Zafari M; Benjamin CD; Miller S; Hochman PS; Whitty A
Biochemistry; 2000 Mar; 39(10):2538-51. PubMed ID: 10704203
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.
Arduini RM; Strauch KL; Runkel LA; Carlson MM; Hronowski X; Foley SF; Young CN; Cheng W; Hochman PS; Baker DP
Protein Sci; 1999 Sep; 8(9):1867-77. PubMed ID: 10493588
[TBL] [Abstract][Full Text] [Related]
18. [Mutation of LoopAB in HuIFN 1c/86D and enhancement of antiviral activity].
Hu R; Ma X; Wei K; Wang H; Qian Z; Xue S; Duan Z; Hou Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):132-5. PubMed ID: 12196823
[TBL] [Abstract][Full Text] [Related]
19. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.
Kalie E; Jaitin DA; Podoplelova Y; Piehler J; Schreiber G
J Biol Chem; 2008 Nov; 283(47):32925-36. PubMed ID: 18801736
[TBL] [Abstract][Full Text] [Related]
20. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
